Abstract C271: FAK inhibitor defactinib (VS-6063) enhances the efficacy of paclitaxel and preferentially targets ovarian cancer stem cells.

Christian M. Vidal; Vihren N. Kolev; Quentin G. Wright; Winnie F. Tam; David T. Weaver; Mahesh V. Padval; Qunli Xu; Jonathan A. Pachter

doi:10.1158/1535-7163.TARG-13-C271

Therapeutic Agents: Small Molecule Kinase Inhibitors

Abstract C271: FAK inhibitor defactinib (VS-6063) enhances the efficacy of paclitaxel and preferentially targets ovarian cancer stem cells.

Christian M. Vidal, Vihren N. Kolev, Quentin G. Wright, Winnie F. Tam, David T. Weaver, Mahesh V. Padval, Qunli Xu and Jonathan A. Pachter

Christian M. Vidal

Verastem, Cambridge, MA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Vihren N. Kolev

Verastem, Cambridge, MA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Quentin G. Wright

Verastem, Cambridge, MA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Winnie F. Tam

Verastem, Cambridge, MA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

David T. Weaver

Verastem, Cambridge, MA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mahesh V. Padval

Verastem, Cambridge, MA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Qunli Xu

Verastem, Cambridge, MA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jonathan A. Pachter

Verastem, Cambridge, MA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

DOI: 10.1158/1535-7163.TARG-13-C271 Published November 2013

Article
Info & Metrics

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: January 2014 to January 2021

	Abstract	Full-text HTML	PDF
Total	1281	0	70

Cited By

Article Information

Volume 12, Issue 11 Supplement, pp. C271

DOI

https://doi.org/10.1158/1535-7163.TARG-13-C271

Published By

American Association for Cancer Research

Print ISSN

1535-7163

Online ISSN

1538-8514

Author Information

Christian M. Vidal,
Vihren N. Kolev,
Quentin G. Wright,
Winnie F. Tam,
David T. Weaver,
Mahesh V. Padval,
Qunli Xu, and
Jonathan A. Pachter

Verastem, Cambridge, MA

Molecular Cancer Therapeutics: 12 (11 Supplement)

November 2013
Volume 12, Issue 11 Supplement

Table of Contents

Search for this keyword

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Abstract C271: FAK inhibitor defactinib (VS-6063) enhances the efficacy of paclitaxel and preferentially targets ovarian cancer stem cells.

Message Subject (Your Name) has forwarded a page to you from Molecular Cancer Therapeutics

Message Body (Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Abstract C271: FAK inhibitor defactinib (VS-6063) enhances the efficacy of paclitaxel and preferentially targets ovarian cancer stem cells.

Christian M. Vidal, Vihren N. Kolev, Quentin G. Wright, Winnie F. Tam, David T. Weaver, Mahesh V. Padval, Qunli Xu and Jonathan A. Pachter

Mol Cancer Ther November 1 2013 (12) (11 Supplement) C271; DOI: 10.1158/1535-7163.TARG-13-C271

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Abstract C271: FAK inhibitor defactinib (VS-6063) enhances the efficacy of paclitaxel and preferentially targets ovarian cancer stem cells.

Christian M. Vidal, Vihren N. Kolev, Quentin G. Wright, Winnie F. Tam, David T. Weaver, Mahesh V. Padval, Qunli Xu and Jonathan A. Pachter

Mol Cancer Ther November 1 2013 (12) (11 Supplement) C271; DOI: 10.1158/1535-7163.TARG-13-C271

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Info & Metrics

Cited By...

Therapeutic Agents: Small Molecule Kinase Inhibitors

Abstract C091: Preclinical evaluation of PK, PD, and antitumor activity of the oral, non-covalent, potent and highly selective CDK7 inhibitor, SY-5609, provides rationale for clinical development in multiple solid tumor indications
Abstract C078: Substituted oxindoles as AMP-activated protein kinase (AMPK) inhibitors and their evaluation in models of leukemia
Abstract C086: Immunotherapeutic effects of the TYK2 inhibitor SAR-20351 in syngeneic tumor models

Show more Therapeutic Agents: Small Molecule Kinase Inhibitors

Therapeutic Agents: Small Molecule Kinase Inhibitors: Poster Presentations - Proffered Abstracts

Abstract C087: Phase 1 study of DCC-3014, an oral inhibitor of CSF1R, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors, including diffuse-type tenosynovial giant cell tumor
Abstract C082: AGX-73, a novel small molecule multi-immunokinase inhibitor, has robust antitumor activity in murine syngeneic tumor models as a single agent and in combination with anti-PD1 checkpoint inhibitor
Abstract C092: Axl inhibitor TP-0903 augments chemo- and immunotherapy efficacy in pancreatic cancer

Show more Therapeutic Agents: Small Molecule Kinase Inhibitors: Poster Presentations - Proffered Abstracts

Main menu

User menu

Search

Abstract C271: FAK inhibitor defactinib (VS-6063) enhances the efficacy of paclitaxel and preferentially targets ovarian cancer stem cells.

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: January 2014 to January 2021

Cited By

Article Information

Author Information

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Therapeutic Agents: Small Molecule Kinase Inhibitors

Therapeutic Agents: Small Molecule Kinase Inhibitors: Poster Presentations - Proffered Abstracts

Articles

Info for

About MCT